NEW YORK, Jan. 31, 2017 /PRNewswire/ -- Global Hemophilia Treatment Drugs Market: OverviewHemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary disorder, passed from parents to the child. Hemophilia is a bleeding disorder which causes excess bleeding and poor blood clotting. The people with hemophilia are generally known as hemophiliacs. There are two main type of hemophilia, hemophilia A and hemophilia B. Hemophilia A or classical hemophilia is the most common type of hemophilia, caused by lack of factor VIII in blood. Hemophilia B also known as Christmas disease, as it was firstly diagnosed in person named Steven Christmas. Hemophilia B is caused by lack of factor IX in blood. Other hemophilia are hemophilia C, Acquired Hemophilia etc. Hemophilia A & B is passed from mother to child, but hemophilia C is passed from both mother and father to child. This report analyzes the current and future prospects of the hemophilia treatment drugs market based on type of product, disease indication, distribution channel and geography.Global Hemophilia Treatment Drugs Market: Research MethodologyThe research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major radiography techniques in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each Product type, disease indication, distribution channel, and geography for the period 2015 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for disease indication was calculated on the basis of prevalence of diseases in humans.Global Hemophilia Treatment Drugs Market: ScopeThe market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of product, disease indication, distribution channel and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influence the hemophilia treatment drugs market in the current and future scenario. The report also provides value chain analysis of the market that describes the sequence of activities involved from manufacturing to their final reach to the end users.Global Hemophilia Treatment Drugs Market: Regional OutlookMarket share analysis among the market players is analyzed to signify percentage share of the major players operating in the market. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for countries of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.Key Players Mentioned in the Report are:The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the hemophilia treatment drugs market report are Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Pfizer Inc., Biotest AG, Kedrion Pharma, Inc., Octapharma AG, Shire Plc, Biogen and some other players who are involved in the hemophilia treatment drugs market.The global hemophilia treatment drugs market is segmented as follows:Global Hemophilia Treatment Drugs Market Revenue, by Product typeRecombinant coagulation factor concentratesFactor VIIIFactor IXCombinationPlasma derived coagulation factor concentratesFactor VIIIFactor IXCombinationDesmopressinAntifibrinolytic agentsGlobal Hemophilia Treatment Drugs Market Revenue, by Disease IndicationHemophilia AHemophilia BOthersGlobal Hemophilia Treatment Drugs Market Revenue, by Distribution ChannelHospital PharmaciesRetail PharmaciesE-commerceGlobal Hemophilia Treatment Drugs Market Revenue, by GeographyNorth AmericaU.S.CanadaEuropeGermanyFranceItalySpainU.K.Rest of EuropeAsia PacificChinaJapanIndiaAustralia & New ZealandRest of Asia PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East and AfricaSaudi ArabiaSouth AfricaRest of Middle East & AfricaRead the full report: http://www.reportlinker.com/p04662500-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hemophilia-treatment-drugs-market---global-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-300400080.html
SOURCE Reportlinker
